CRIS Current Research Information System

RODA, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.728
AS - Asia 4.976
EU - Europa 4.500
AF - Africa 328
SA - Sud America 242
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.783
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.694
SG - Singapore 1.419
VN - Vietnam 1.408
CN - Cina 1.334
GB - Regno Unito 1.263
SE - Svezia 588
DE - Germania 565
IT - Italia 527
UA - Ucraina 411
HK - Hong Kong 316
RU - Federazione Russa 270
IN - India 231
FR - Francia 199
IE - Irlanda 190
BR - Brasile 161
NL - Olanda 102
EE - Estonia 93
CI - Costa d'Avorio 92
ZA - Sudafrica 87
JP - Giappone 84
KR - Corea 81
CH - Svizzera 73
TG - Togo 59
FI - Finlandia 54
SC - Seychelles 47
GR - Grecia 34
NG - Nigeria 31
AR - Argentina 30
JO - Giordania 30
BE - Belgio 29
BG - Bulgaria 27
PL - Polonia 23
CA - Canada 19
EC - Ecuador 19
IR - Iran 19
ES - Italia 13
BD - Bangladesh 12
MX - Messico 11
TR - Turchia 10
CL - Cile 9
AT - Austria 8
ID - Indonesia 8
LT - Lituania 7
CO - Colombia 6
CZ - Repubblica Ceca 6
PY - Paraguay 6
HR - Croazia 5
LB - Libano 5
AU - Australia 4
DK - Danimarca 4
PE - Perù 4
PK - Pakistan 4
VE - Venezuela 4
IL - Israele 3
MA - Marocco 3
PH - Filippine 3
AL - Albania 2
EG - Egitto 2
EU - Europa 2
KE - Kenya 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RO - Romania 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BB - Barbados 1
BO - Bolivia 1
CG - Congo 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
GL - Groenlandia 1
GN - Guinea 1
HU - Ungheria 1
KZ - Kazakistan 1
LV - Lettonia 1
MM - Myanmar 1
NI - Nicaragua 1
NO - Norvegia 1
SA - Arabia Saudita 1
TL - Timor Orientale 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 15.783
Salva come PNG Salva come JPEG
Città #
Southend 1.116
Singapore 955
Fairfield 567
Chandler 559
Ashburn 552
Santa Clara 393
Hong Kong 315
Jacksonville 300
Ho Chi Minh City 281
Dong Ket 256
Princeton 233
Hanoi 232
Wilmington 230
Woodbridge 218
Ann Arbor 216
Hefei 213
Houston 201
Beijing 197
Dublin 188
Seattle 178
Boardman 162
Cambridge 153
Nanjing 105
Westminster 104
Padova 101
Abidjan 92
Los Angeles 86
Tokyo 82
Seoul 77
Berlin 71
Bern 63
Buffalo 62
Saint Petersburg 60
Lomé 59
Medford 57
Milan 55
Bologna 52
New York 51
Helsinki 48
Jinan 47
Hebei 43
Mülheim 43
Da Nang 42
Shenyang 39
Haiphong 37
Dearborn 36
Nanchang 36
Mahé 33
Changsha 31
Amman 30
Dallas 30
San Diego 30
Abeokuta 29
Munich 29
Turin 29
Brussels 27
Frankfurt am Main 25
Quận Bình Thạnh 24
Sofia 24
Thái Nguyên 24
Falkenstein 23
Guangzhou 23
Shanghai 23
Des Moines 22
Mountain View 22
Redondo Beach 22
São Paulo 22
Verona 22
Florence 21
Hải Dương 21
Tianjin 21
Biên Hòa 20
Ha Long 20
Hangzhou 18
Jiaxing 18
Redwood City 18
Kunming 17
Norwalk 17
Bắc Ninh 16
London 16
Can Tho 15
Falls Church 15
Bengaluru 14
Lanzhou 14
Vinh 14
Zhengzhou 14
Haikou 13
Yubileyny 13
Chicago 12
Leawood 12
Ninh Bình 12
Vũng Tàu 12
Wuhan 12
Bremen 11
Chengdu 11
Ningbo 11
Pune 11
Monmouth Junction 10
Olalla 10
Quito 10
Totale 10.276
Salva come PNG Salva come JPEG
Nome #
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 574
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 486
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 320
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 280
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 260
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 260
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 226
13C-urea breath test to assess Helicobacter pylori bacterial load. 224
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 222
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 213
Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. 206
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 198
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 195
Intestinal epithelial cells in inflammatory bowel diseases 194
A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: a pilot study 193
A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon 190
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 183
Chemiluminescence quantitative immunohistochemical determination of MRP2 in liver biopsies. 178
Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations. 173
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. 172
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 168
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 166
Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. 164
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 160
Infezioni da Helicobacter Pylori e sintomi da reflusso gastro-esofageo nelle donne in gravidanza 159
Inflammatory bowel disease: Moving toward a stem cell-based therapy 158
Ribavirin for chronic hepatitis C: And the mystery goes on. 157
Pharmacological modulation of MRP2 in primary biliary cirrhosis 152
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 152
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 152
Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis 149
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 148
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 148
FXR activity modulation by bile acids and analogs assessed with a recombinant HepG2 cell-based luciferase assay. 147
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 147
Sviluppo di un biosensore luminescente basato su una linea cellulare ricombinante di epatocarcinoma umano (HepG2) per la determinazione dell’attività di acidi biliarinaturali e sintetici 146
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. 144
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 144
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 142
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 141
Safety of interferon beta treatment for chronic HCV hepatitis. 140
Pharmacokinetics and safety of a new 1200 mg single-dose delayed release mesalazine microgranule formulation 139
Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man 139
Management of hepatic encephalopathy: focus on antibiotic therapy 137
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 136
Alimentazione e prevenzione: la salute vien mangiando 136
Quantitative immunohistochemistry and in situ hybridization imaging procedures with luminescence detection: a new potential diagnostic tool 135
Quantitative immunohistochemistry and in situ hybridization with luminescence detection: a new potential diagnostic tool 135
Quantitative immunohistochemistry and in situ hybridization with luminescence detection: a new potential diagnostic tool 134
Serum TUDCA/UDCA concentration profiles after TUDCA oral load: A new test for intestinal transit time and bacteria overgrowth evaluation 132
SELECTIVE SOLID PHASE EXTRACTION FOR DIRECT MALDI-TOF MS PROFILING OF SERUM PROTEINS 132
MALDI-TOF MS protein profiling using selective extraction with derivatized cellulose and chemometric analysis: from hepatitis C to hepatocellular carcinoma 132
Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. 132
Reduced biliary sterol output with no change in total faecal excretion in mice expressing a human apolipoprotein A-I variant 131
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 130
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 129
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 128
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project). 128
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 126
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations 124
Hepatic steatosis in obese patients: clinical aspects and prognostic significance. 123
UDCA UP-REGULATES HUMAN PLACENTAL BCRP EXPRESSION: PRELIMINARY RESULTS 123
Hypertransaminasemia and pregnancy outcome. 121
Reflux symptoms and Helicobacter pylori in pregnancy 119
Salivary TUDCA concentration profiles after TUDCA oral load: a non-invasive test for intestinal transit time evaluation 118
Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. 115
Nuovo metodo per l’arricchimento ed il controllo del processo differenziativo di cellule staminali umane 114
UDCA UP-REGULATES HUMAN PLACENTAL OATP-A EXPRESSION IN INTRAHEPATIC CHOLESTASIS OF PREGNANCY 113
Placental MRP2 is upregulated by UDCA in cholestasis of pregnancy. 112
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study 112
Genetic polymorphisms of PPAR-alpha: allele frequency in gallstone patients. 111
Modulation of placental bilirubin and bile acids transporters during cholestasis of pregnancy. 111
New tools to monitor stem cells enrichment and differentiation processes by Field-Flow Fractionation 110
Intestinal microflora and motility in gallstones before and after cholecystectomy: any role for gallstone pathogenesis? 110
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 110
ESWL for difficult bile duct stones: a 15-year single centre experience. 110
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 109
Selective solid phase extraction for direct MALDI-TOF MS profiling of serum proteins 109
Is it possible to predict the clinical course of gallstone disease? Usefulness of gallbladder motility evaluation in a clinical setting 108
RIBAVIRIN PRIMING ENHANCES EFFICACY OF CHRONIC HEPATITIS C RE-TREATMENT IN PATIENTS WHO HAD NOT RESPONDED TO PREVIOUS COMBINATION THERAPY 105
Enhanced response to peginterferon-alpha-2a based triple therapy in previously non-responsive chronic hepatitis C: Final results of PRETTY study. 104
Liver transplantation for cholestatic liver diseases: a single center experience 102
Malattia litiasica. 100
SELECTIVE SOLID PHASE EXTRACTION FOR DIRECT MALDI-TOF MS PROFILING OF SERUM PROTEINS 100
Quantitative immunohistochemistry and in situ hybridization imaging procedures with luminescence detection: a new potential diagnostic tool 100
Effect of chronic administration of ursodeoxycholic acid on gallbladder and gastro-intestinal motility in gallstone patients and healthy controls 98
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease 98
Effects of cholesterol 7alpha-hydroxylase promoter polymorphisms on basal promoter activity and feedback regulation of bile acid synthesis 97
Treatment of acute hepatitis B with high dose lamivudine 93
Prevalence of different PPAR-alpha gene polymorphisms and haplotypes in gallstone patients. Dig Liv Dis 2005;Vol. 37 Suppl.1:S36. 93
Metabolic, nutritional and immunological parameters in healthy volunteers after inulin and saccharose feeding 89
Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels 89
Prospective evaluation of aberrant p16 methylation in serum of patients before and after therapy for localized HCC. 89
Safety of interferon β treatment for chronic HCV hepatitis 88
Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients 88
Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence 87
Hospitalization for peptic ulcer bleeding: role of HP status and NSAIDS. 86
Cholic acid metabolism in human fecal cultures during diet supplementation with Lactobacillus rhamnosus GG 79
Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial 78
Bile acid active and passive ileal transport in the rabbit: effect of luminal stirring 77
Totale 14.744
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021912 0 0 0 0 0 77 27 95 119 80 73 441
2021/20222.235 241 97 130 165 167 125 29 103 117 149 577 335
2022/20232.241 259 323 125 266 149 165 62 107 385 51 215 134
2023/2024542 22 87 38 85 56 104 24 26 30 37 12 21
2024/20252.408 70 435 200 151 522 135 119 68 31 154 56 467
2025/20263.342 1.120 511 500 345 702 164 0 0 0 0 0 0
Totale 15.998